Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.

Faye A SharpleyRicha ManwaniAviva PetrieShameem MahmoodSajitha SachchithananthamHelen J LachmannAna Martinez De Azcona NaharroJulian D GillmoreCarol J WhelanMarianna FontanaOliver CohenPhilip N HawkinsAshutosh D Wechalekar

Published in: European journal of haematology (2021)

This small retrospective study suggests that there is no clear survival advantage of ASCT over bortezomib therapy. A prospective randomised controlled trial evaluating ASCT in AL amyloidosis is critically needed.

Keyphrases

stem cell transplantation
multiple myeloma
high dose
study protocol
cell therapy
bone marrow
randomized controlled trial
low dose
cross sectional
platelet rich plasma
clinical trial
stem cells
mesenchymal stem cells